TL-139

Phase I: Primary objectives: To evaluate the safety and tolerability of TL139 in the treatment of patients with locally advanced or metastatic tumors carrying NTRK, ROS1 or ALK fusion genes, explore the maximum tolerated dose (MTD), and select the recommended dose (RP2D) for Phase II clinical trials. Secondary objectives: (1) To evaluate the pharmacokinetic characteristics of TL139. (2) To preliminarily evaluate the anti-tumor efficacy of TL139. (3) To evaluate the effect of high-fat food on TL139. Phase II: Primary objectives: To evaluate the efficacy of TL139 in the treatment of patients with locally advanced or metastatic tumors carrying NTRK, ROS1 or ALK fusion genes. Secondary objectives: (1) To evaluate the safety of TL139 in the treatment of patients with locally advanced or metastatic tumors carrying NTRK, ROS1 or ALK fusion genes. (2) To evaluate the population pharmacokinetic (PK) characteristics of TL139 in the treatment of patients with locally advanced or metastatic tumors carrying NTRK, ROS1 or ALK fusion genes.